Figure 7

Effects of luteolin on cMet/Akt/ERK signaling pathways (a) Western blot analysis of MKN45 and SGC7901 cells treated with varying concentrations of luteolin (0–80 μM) for 24 h. (b) Western blot analysis of MKN45 cells treated with varying concentrations of luteolin (0–80 μM) for 6 h. (c) Western blot analysis of AGS cells treated with varying concentrations of luteolin (0–80 μM) for 24 h. (d) cMet/Akt/ERK status in MKN45 cells incubated for 24 h with LY294002 (a PI3K inhibitor; 20 μM), luteolin (40 μM) or both. (e) Western blot analysis of the possible involvement of Akt/ERK in cell apoptosis and invasiveness. MKN45 cells were incubated for 24 h with either LY294002 (20 μM), PD98059 (50 μM), luteolin (40 μM), or a combination of LY294002 and PD98059. GAPDH was used as a loading control. The blots shown are representative of those from at least three independent experiments.